Pentoxifylline (Tablets, Capsules, Solution, Concentrate) Instructions for Use
ATC Code
C04AD03 (Pentoxifylline)
Active Substance
Pentoxifylline (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Drug improving microcirculation. Angioprotector
Pharmacotherapeutic Group
Peripheral vasodilators; purine derivatives
Pharmacological Action
A microcirculation-improving agent, angioprotector, dimethylxanthine derivative. Pentoxifylline reduces blood viscosity, causes platelet disaggregation, increases the elasticity of erythrocytes (by acting on pathologically altered erythrocyte deformability), improves microcirculation and increases the concentration of oxygen in tissues.
It increases the concentration of cAMP in platelets and ATP in erythrocytes with simultaneous saturation of the energy potential, which in turn leads to vasodilation, a decrease in total peripheral vascular resistance, an increase in stroke volume and minute volume of blood without a significant change in heart rate.
By dilating the coronary arteries, it increases oxygen delivery to the myocardium; by dilating the pulmonary vessels, it improves blood oxygenation. It increases the tone of the respiratory muscles (intercostal muscles and diaphragm).
Intravenous administration, along with the above action, leads to enhanced collateral circulation, an increase in the volume of blood flowing per unit cross-section.
It increases the concentration of ATP in the brain and has a beneficial effect on the bioelectrical activity of the CNS. It improves microcirculation in areas of impaired blood supply.
In occlusive lesions of peripheral arteries (intermittent claudication), it leads to an increase in walking distance, elimination of nocturnal calf muscle cramps and pain at rest.
Pharmacokinetics
After oral administration, it is well absorbed from the gastrointestinal tract. There is a slight metabolism during the first pass through the liver. It binds to erythrocyte membranes. It undergoes biotransformation first in erythrocytes, then in the liver. Some metabolites are active. The T1/2 of the unchanged substance from plasma is 0.4-0.8 hours, for metabolites – 1-1.6 hours. After 24 hours, most of the dose is excreted in the urine as metabolites, a smaller part (about 4%) – through the intestines.
The elimination of pentoxifylline is reduced in elderly patients and in patients with liver diseases.
Indications
Peripheral circulation disorders (including intermittent claudication) associated with chronic occlusive circulatory disorders in the arterial vessels of the lower extremities. Ischemic cerebrovascular accident, ischemic stroke and post-stroke conditions; cerebral atherosclerosis (dizziness, headache, memory impairment, sleep disorders), dyscirculatory encephalopathy, viral neuroinfection (prevention of possible microcirculation disorders). Coronary artery disease, condition after myocardial infarction. Diabetic angiopathy. Acute circulatory disorders in the retina and choroid, acute ischemic optic neuropathy. Otosclerosis, degenerative changes against the background of pathology of the vessels of the inner ear with gradual hearing loss. Chronic obstructive pulmonary disease, bronchial asthma. Impotence of vascular origin.
ICD codes
| ICD-10 code | Indication |
| A89 | Viral infection of the central nervous system, unspecified |
| F07 | Personality and behavioral disorders due to disease, damage or dysfunction of the brain |
| G45 | Transient cerebral ischemic attacks [TIAs] and related syndromes |
| G93.4 | Unspecified encephalopathy |
| H34 | Retinal vascular occlusions |
| H35.0 | Background retinopathy and retinal vascular changes |
| H36.0 | Diabetic retinopathy |
| H47.0 | Disorders of optic nerve, not elsewhere classified (including ischemic optic neuropathy) |
| H80 | Otosclerosis |
| H93.0 | Degenerative and vascular disorders of ear |
| I20 | Angina pectoris |
| I21 | Acute myocardial infarction |
| I63 | Cerebral infarction |
| I67.2 | Cerebral atherosclerosis |
| I69 | Sequelae of cerebrovascular diseases |
| I73.0 | Raynaud's syndrome |
| I73.1 | Obliterative thromboangiitis [Buerger's disease] |
| I73.8 | Other specified peripheral vascular diseases |
| I73.9 | Peripheral vascular disease, unspecified (including intermittent claudication, arterial spasm) |
| I79.2 | Peripheral angiopathy in diseases classified elsewhere (including diabetic angiopathy) |
| J44 | Other chronic obstructive pulmonary disease |
| J45 | Asthma |
| N48.4 | Impotence of organic origin |
| ICD-11 code | Indication |
| 1C8Z | Viral infections of the central nervous system, unspecified |
| 4A44.8 | Thromboangiitis obliterans |
| 6E68 | Secondary emotionally labile personality disorder |
| 6E6Z | Unspecified secondary mental or behavioral syndromes |
| 8B10.Z | Transient ischemic attack, unspecified |
| 8B11 | Cerebral ischemic stroke |
| 8B25.Z | Sequelae of cerebrovascular disease, unspecified |
| 8E47 | Encephalopathy, not elsewhere classified |
| 8E4A.0 | Paraneoplastic or autoimmune disorders of the central nervous system, including brain and spinal cord |
| 8E63 | Post-cardiopulmonary bypass encephalopathy |
| 9B71.0Z | Diabetic retinopathy, unspecified |
| 9B74.Z | Retinal vascular occlusion, unspecified |
| 9B78.1Z | Background retinopathy and retinal vascular changes, unspecified |
| 9C40.Z | Disorders of optic nerve, unspecified |
| AB33 | Otosclerosis |
| AB71 | Degenerative or vascular disorders of the ear |
| BA40.Z | Angina pectoris, unspecified |
| BA41.Z | Acute myocardial infarction, unspecified |
| BD42.0 | Raynaud's disease |
| BD42.1 | Raynaud's syndrome |
| BD42.Z | Raynaud's phenomenon, unspecified |
| BD4Z | Chronic obliterative arterial diseases, unspecified |
| BD53.Y | Other specified secondary involvement of arteries and arterioles |
| BD55 | Asymptomatic stenosis of intracranial or extracranial artery |
| BD5Z | Diseases of arteries or arterioles, unspecified |
| CA22.Z | Chronic obstructive pulmonary disease, unspecified |
| CA23 | Asthma |
| EG00 | Dilation of skin vessels of the extremities |
| HA01.1Z | Male erectile dysfunction, unspecified |
| MB40.7 | Acroparesthesia |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Tablets
The duration of treatment and the dosing regimen for Pentoxifylline are established individually by the attending physician, depending on the clinical picture of the disease and the therapeutic effect achieved.
The drug is taken orally immediately after meals, without chewing, with a sufficient amount of liquid.
For adults, the drug is prescribed starting from 200 mg 3 times/day.
Prolonged-release dosage forms are prescribed 2 times/day. The course of treatment is 2-3 weeks or more.
Solution
The drug can be administered intravenously, intra-arterially.
Intravenous drip infusion is administered slowly at a dose of 100 mg in 250-500 ml of isotonic sodium chloride solution or in a 5% glucose solution (duration of administration – 90-180 min); intra-arterially – first at a dose of 100 mg in 20-50 ml of isotonic sodium chloride solution, and on subsequent days – 200-300 mg in 30-50 ml of solvent.
Rate of administration: 100 mg (5 ml of 2% pentoxifylline solution) over 10 min.
Capsules, Concentrate
Used intra-arterially (bolus or drip), intravenously (bolus or drip), intramuscularly, orally. The dose and treatment regimen are established individually.
Adverse Reactions
From the CNS headache, dizziness; anxiety, sleep disorders, convulsions.
Dermatological reactions skin hyperemia, flushing of the skin of the face and upper chest, edema, increased brittleness of nails.
From the digestive system dry mouth, decreased appetite, intestinal atony, exacerbation of cholecystitis, cholestatic hepatitis, increased activity of hepatic transaminases and alkaline phosphatase.
From the organ of vision visual impairment, scotoma.
From the cardiovascular system tachycardia, arrhythmia, cardialgia, progression of angina, decreased blood pressure.
From the hematopoietic system thrombocytopenia, leukopenia, pancytopenia.
From the blood coagulation system hypofibrinogenemia, bleeding from skin vessels, mucous membranes, stomach, intestines.
Allergic reactions itching, skin hyperemia, urticaria, angioedema, anaphylactic shock.
Contraindications
Acute myocardial infarction, porphyria, massive bleeding, hemorrhagic stroke, retinal hemorrhage, pregnancy, lactation period. For intravenous administration (additionally) – arrhythmias, severe atherosclerosis of coronary or cerebral arteries, uncontrolled arterial hypotension.
Hypersensitivity to pentoxifylline and other xanthine derivatives.
Use in Pregnancy and Lactation
Adequate and well-controlled clinical studies on the safety of pentoxifylline use during pregnancy have not been conducted.
Pentoxifylline and its metabolites are excreted in breast milk. If use during lactation is necessary, breastfeeding should be discontinued.
Use in Hepatic Impairment
In severe liver function disorders, correction of the pentoxifylline dosing regimen is required.
Use in Renal Impairment
In renal function disorders, correction of the pentoxifylline dosing regimen is required.
Pediatric Use
Use with caution in children and adolescents under 18 years of age (efficacy and safety have not been studied).
Special Precautions
Use with caution in cases of labile blood pressure (tendency to arterial hypotension), chronic heart failure, gastric and duodenal ulcer (for oral administration), after recent surgical interventions, in hepatic and/or renal failure, in children and adolescents under 18 years of age (efficacy and safety have not been studied).
In cases of renal impairment or severe hepatic impairment, correction of the pentoxifylline dosing regimen is required.
Blood pressure levels should be monitored during treatment.
With simultaneous use with antihypertensive agents, insulin, oral hypoglycemic drugs, a reduction in the dose of pentoxifylline may be required.
With simultaneous use with anticoagulants, blood coagulation parameters should be carefully monitored.
Drug Interactions
Pentoxifylline may potentiate the effect of antihypertensive drugs.
Against the background of parenteral use of pentoxifylline in high doses, an enhancement of the hypoglycemic effect of insulin in patients with diabetes mellitus is possible.
With simultaneous use with ketorolac, an increased risk of bleeding and/or increased prothrombin time is possible; with meloxicam – an increased risk of bleeding; with sympatholytics, ganglion blockers and vasodilators – a decrease in blood pressure is possible; with heparin, fibrinolytic drugs – enhancement of the anticoagulant effect.
Cimetidine significantly increases the plasma concentration of pentoxifylline, therefore, with simultaneous use, the likelihood of adverse effects may increase.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Retard tablets, film-coated, 400 mg: 10, 20, 30, 40, 50, 60, 80, 100, 120, 200 pcs.
Enteric-coated tablets, 100 mg: 10, 20, 30, 40, 50, 60, 80, 100, 120, or 200 pcs.
Marketing Authorization Holder
Shreya Life Sciences, Pvt.Ltd. (India)
Dosage Forms
 |
Pentoxifylline | Retard tablets, film-coated, 400 mg: 10, 20, 30, 40, 50, 60, 80, 100, 120, 200 pcs. |
| Enteric-coated tablets, 100 mg: 10, 20, 30, 40, 50, 60, 80, 100, 120, or 200 pcs. |
Dosage Form, Packaging, and Composition
Enteric-coated tablets pink, film-coated; round, biconvex.
| 1 tab. | |
| Pentoxifylline | 100 mg |
Excipients: microcrystalline cellulose, dibasic calcium phosphate, polyvinylpyrrolidone, magnesium stearate, sodium croscarmellose, talc.
Coating composition: methacrylic acid copolymer, diethyl phthalate, titanium dioxide, carmoisine lake.
10 pcs. – blisters (6) – cardboard packs.
Retard tablets, film-coated pink, capsule-shaped, with a break line on one side.
| 1 tab. | |
| Pentoxifylline | 400 mg |
Excipients: ethylcellulose, dibasic calcium phosphate, magnesium stearate, talc.
Coating composition: titanium dioxide, hypromellose, diethyl phthalate, carmoisine lake.
10 pcs. – blisters (2) – cardboard packs.
Solution for injection 20 mg/1 ml: amp. 3, 5, 6, 9, 10, 12, 15, 20, 30, or 40 pcs.
Solution for injection 40 mg/2 ml: amp. 3, 5, 6, 9, 10, 12, 15, 20, 30, or 40 pcs.
Solution for injection 100 mg/5 ml: amp. 3, 5, 6, 9, 10, 12, 15, 20, 30, or 40 pcs.
Marketing Authorization Holder
Shreya Life Sciences, Pvt.Ltd. (India)
Dosage Forms
|
Pentoxifylline | Solution for injection 20 mg/1 ml: amp. 3, 5, 6, 9, 10, 12, 15, 20, 30, or 40 pcs. |
| Solution for injection 40 mg/2 ml: amp. 3, 5, 6, 9, 10, 12, 15, 20, 30, or 40 pcs. | ||
| Solution for injection 100 mg/5 ml: amp. 3, 5, 6, 9, 10, 12, 15, 20, 30, or 40 pcs. |
Dosage Form, Packaging, and Composition
Solution for injection clear, colorless or slightly yellowish.
| 1 ml | |
| Pentoxifylline | 20 mg |
Excipients: sodium chloride, water for injections.
1 ml – ampoules (5) – polyethylene trays (1) – cardboard boxes.
Solution for injection clear, colorless or slightly yellowish.
| 1 ml | 1 amp. | |
| Pentoxifylline | 20 mg | 40 mg |
Excipients: sodium chloride, water for injections.
2 ml – ampoules (5) – polyethylene trays (1) – cardboard boxes.
Solution for injection clear, colorless or slightly yellowish.
| 1 ml | 1 amp. | |
| Pentoxifylline | 20 mg | 100 mg |
Excipients: sodium chloride, water for injections.
5 ml – ampoules (5) – polyethylene trays (1) – cardboard boxes.
Concentrate for solution for infusion 20 mg/1 ml: 5 ml amp. 5 or 10 pcs.
Marketing Authorization Holder
Alvils, LLC (Russia)
Manufactured By
Northeast Pharmaceutical Group Co., Ltd (China)
Dosage Form
|
Pentoxifylline | Concentrate for solution for infusion 20 mg/1 ml: 5 ml amp. 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Concentrate for solution for infusion in the form of a clear, colorless or slightly colored liquid.
| 1 ml | |
| Pentoxifylline | 20 mg |
Excipients: water for injections – up to 1 ml.
5 ml – ampoules of colorless glass (5) – blisters (1) – cardboard packs.
5 ml – ampoules of colorless glass (5) – blisters (2) – cardboard packs.
5 ml – ampoules of colorless glass (10) – blisters (1) – cardboard packs.
Enteric-coated tablets, 100 mg: 10, 14, 20, 25, 28, 30, 40, 42, 50, 56, 60, 70, 75, 84, 90, 100, 120, 125, 150, 168, 180, 300, or 360 pcs.
Marketing Authorization Holder
Atoll LLC (Russia)
Manufactured By
Ozon, LLC (Russia)
Dosage Form
|
Pentoxifylline | Enteric-coated tablets, 100 mg: 10, 14, 20, 25, 28, 30, 40, 42, 50, 56, 60, 70, 75, 84, 90, 100, 120, 125, 150, 168, 180, 300, or 360 pcs. |
Dosage Form, Packaging, and Composition
Enteric-coated tablets white or almost white in color; round, cylindrical, biconvex in shape; on the cross-section, a film coating and a core of white or almost white color are visible.
| 1 tab. | |
| Pentoxifylline | 100 mg |
Excipients: lactose monohydrate (milk sugar) – 53.42 mg, potato starch – 18 mg, povidone K25 – 7.2 mg, methylcellulose – 0.48 mg, magnesium stearate – 0.9 mg.
Enteric coating composition: acryl-iz white 93A – 7.2 mg, including: methacrylic acid and ethyl acrylate copolymer (1:1) – 4.752 mg, talc – 1.188 mg, titanium dioxide – 1.08 mg, colloidal silicon dioxide – 0.072 mg, sodium bicarbonate – 0.072 mg, sodium lauryl sulfate – 0.036 mg, triethyl citrate – 0.8 mg.
10 pcs. – contour cell blisters (1) – cardboard packs.
10 pcs. – contour cell blisters (2) – cardboard packs.
10 pcs. – contour cell blisters (3) – cardboard packs.
10 pcs. – contour cell blisters (4) – cardboard packs.
10 pcs. – contour cell blisters (5) – cardboard packs.
10 pcs. – contour cell blisters (6) – cardboard packs.
10 pcs. – contour cell blisters (12) – cardboard packs.
14 pcs. – contour cell blisters (1) – cardboard packs.
14 pcs. – contour cell blisters (2) – cardboard packs.
14 pcs. – contour cell blisters (3) – cardboard packs.
14 pcs. – contour cell blisters (4) – cardboard packs.
14 pcs. – contour cell blisters (5) – cardboard packs.
14 pcs. – contour cell blisters (6) – cardboard packs.
14 pcs. – contour cell blisters (12) – cardboard packs.
25 pcs. – contour cell blisters (1) – cardboard packs.
25 pcs. – contour cell blisters (2) – cardboard packs.
25 pcs. – contour cell blisters (3) – cardboard packs.
25 pcs. – contour cell blisters (4) – cardboard packs.
25 pcs. – contour cell blisters (5) – cardboard packs.
25 pcs. – contour cell blisters (6) – cardboard packs.
25 pcs. – contour cell blisters (12) – cardboard packs.
30 pcs. – contour cell blisters (1) – cardboard packs.
30 pcs. – contour cell blisters (2) – cardboard packs.
30 pcs. – contour cell blisters (3) – cardboard packs.
30 pcs. – contour cell blisters (4) – cardboard packs.
30 pcs. – contour cell blisters (5) – cardboard packs.
30 pcs. – contour cell blisters (6) – cardboard packs.
30 pcs. – contour cell blisters (12) – cardboard packs.
10 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
20 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
30 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
40 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
50 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
60 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
100 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
120 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
Concentrate for solution for infusion 20 mg/ml: 5 ml amp. 5 or 10 pcs.
Marketing Authorization Holder
Atoll LLC (Russia)
Manufactured By
Ozon, LLC (Russia)
Dosage Form
|
Pentoxifylline | Concentrate for solution for infusion 20 mg/ml: 5 ml amp. 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Concentrate for solution for infusion in the form of a clear, white or slightly colored liquid.
| 1 ml | |
| Pentoxifylline | 20 mg |
Excipients: sodium chloride – 6 mg, sodium dihydrogen phosphate dihydrate – 1 mg, sodium hydroxide solution 0.1 M – to pH 6.0-8.0, water for injection – to 1 ml.
5 ml – ampoules of colorless glass (5) – contour cell blisters (1) – cardboard packs.
5 ml – ampoules of colorless glass (5) – contour cell blisters (2) – cardboard packs.
5 ml – ampoules of colorless glass (5) – cardboard trays (1) – cardboard packs.
5 ml – ampoules of colorless glass (5) – cardboard trays (2) – cardboard packs.
Solution for infusion 2 mg/ml: container 100 ml
Marketing Authorization Holder
Belarusian-Dutch Joint Venture "FARMLAND", LLC (Republic of Belarus)
Dosage Form
|
Pentoxifylline | Solution for infusion 2 mg/ml: container 100 ml |
Dosage Form, Packaging, and Composition
| Solution for infusion | 1 ml |
| Pentoxifylline | 2 mg |
Excipients: sodium chloride 9 mg, water for injection to 1 ml.
100 ml – polymer containers (1) – polyethylene bags.
Solution for intravenous injection 100 mg/5 ml: amp. 5 or 10 pcs.
Marketing Authorization Holder
Binnopharm JSC (Russia)
Dosage Form
|
Pentoxifylline | Solution for intravenous injection 100 mg/5 ml: amp. 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
| Concentrate for preparation of solution for intravenous and intra-arterial administration | 1 ml | 1 amp. |
| Pentoxifylline | 20 mg | 100 mg |
5 ml – ampoules (10) – cardboard packs.
5 ml – ampoules (5) – contour cell blisters (2) – cardboard packs.
5 ml – ampoules (5) – contour cell blisters (1) – cardboard packs.
Enteric-coated tablets, 100 mg: 20, 30, or 60 pcs.
Marketing Authorization Holder
Biosintez, PJSC (Russia)
Dosage Form
|
Pentoxifylline | Enteric-coated tablets, 100 mg: 20, 30, or 60 pcs. |
Dosage Form, Packaging, and Composition
Enteric-coated tablets pink in color, round, biconvex.
| 1 tab. | |
| Pentoxifylline | 100 mg |
Excipients: lactose, water-soluble methylcellulose MC 16, calcium stearate, povidone, potato starch.
Enteric coating composition: cellacephate, titanium dioxide, vaseline oil, talc, castor oil, beeswax, azorubine.
10 pcs. – contour cell blisters (2) – cardboard packs.
10 pcs. – contour cell blisters (3) – cardboard packs.
10 pcs. – contour cell blisters (6) – cardboard packs.
20 pcs. – polymer jars (1) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
60 pcs. – polymer jars (1) – cardboard packs.
20 pcs. – orange glass jars (1) – cardboard packs.
30 pcs. – orange glass jars (1) – cardboard packs.
60 pcs. – orange glass jars (1) – cardboard packs.
Concentrate for solution for intravenous and intra-arterial administration 100 mg/5 ml: amp. 10 pcs.
Marketing Authorization Holder
Borisov Plant Of Medical Preparations, PJSC (Republic Of Belarus)
Dosage Form
|
Pentoxifylline | Concentrate for solution for intravenous and intra-arterial administration 100 mg/5 ml: amp. 10 pcs. |
Dosage Form, Packaging, and Composition
| Concentrate for preparation of solution for intravenous and intra-arterial administration | 1 ml | 1 amp. |
| Pentoxifylline | 20 mg | 100 mg |
5 ml – ampoules (10) – cardboard packs.
5 ml – ampoules (5) – contour cell blisters (2) – cardboard packs.
5 ml – ampoules (5) – contour cell blisters (1) – cardboard packs.
Injection solution 2% (100 mg/5 ml): amp. 10 pcs.
Marketing Authorization Holder
Borisov Plant Of Medical Preparations, PJSC (Republic Of Belarus)
Dosage Form
|
Pentoxifylline | Injection solution 2% (100 mg/5 ml): amp. 10 pcs. |
Dosage Form, Packaging, and Composition
| Injection solution 2% | 1 ml | 1 amp. |
| Pentoxifylline | 20 mg | 100 mg |
5 ml – ampoules (10) – cardboard packs.
Concentrate for solution for infusion 20 mg/1 ml: 5 ml amp. 5 or 10 pcs.
Marketing Authorization Holder
Velpharm, LLC (Russia)
Dosage Form
|
Pentoxifylline | Concentrate for solution for infusion 20 mg/1 ml: 5 ml amp. 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Concentrate for solution for infusion in the form of a clear, colorless or slightly yellowish liquid.
| 1 ml | |
| Pentoxifylline | 20 mg |
Excipients: sodium chloride, sodium dihydrogen phosphate dihydrate (sodium phosphate monobasic dihydrate), sodium hydroxide solution 1M, water for injection – to 1 ml.
5 ml – ampoules of neutral glass (5) – contour cell blisters (1) – cardboard packs.
5 ml – ampoules of neutral glass (5) – contour cell blisters (2) – cardboard packs.
Enteric-coated tablets, 100 mg: 10, 14, 20, 28, 30, 40, 42, 50, 56, 60, 70, 80, 84, 90, 98, 100, 112, 126, or 140 pcs.
Marketing Authorization Holder
Velpharm, LLC (Russia)
Dosage Form
|
Pentoxifylline | Enteric-coated tablets, 100 mg: 10, 14, 20, 28, 30, 40, 42, 50, 56, 60, 70, 80, 84, 90, 98, 100, 112, 126, or 140 pcs. |
Dosage Form, Packaging, and Composition
Enteric-coated tablets white in color, round, biconvex; on the cross-section, the core is white or almost white.
| 1 tab. | |
| Pentoxifylline | 100 mg |
Excipients: lactose monohydrate (milk sugar), potato starch, talc, colloidal silicon dioxide (aerosil), magnesium stearate.
Coating composition[dry mixture for film coating, containing methacrylic acid and ethyl acrylate copolymer 1:1, talc, titanium dioxide, colloidal silicon dioxide (aerosil), sodium bicarbonate, sodium lauryl sulfate], triethyl citrate.
10 pcs. – contour cell blisters (1) – cardboard packs.
10 pcs. – contour cell blisters (2) – cardboard packs.
10 pcs. – contour cell blisters (3) – cardboard packs.
10 pcs. – contour cell blisters (4) – cardboard packs.
10 pcs. – contour cell blisters (5) – cardboard packs.
10 pcs. – contour cell blisters (6) – cardboard packs.
10 pcs. – contour cell blisters (7) – cardboard packs.
10 pcs. – contour cell blisters (8) – cardboard packs.
10 pcs. – contour cell blisters (9) – cardboard packs.
10 pcs. – contour cell blisters (10) – cardboard packs.
14 pcs. – contour cell blisters (1) – cardboard packs.
14 pcs. – contour cell blisters (2) – cardboard packs.
14 pcs. – contour cell blisters (3) – cardboard packs.
14 pcs. – contour cell blisters (4) – cardboard packs.
14 pcs. – contour cell blisters (5) – cardboard packs.
14 pcs. – contour cell blisters (6) – cardboard packs.
14 pcs. – contour cell blisters (7) – cardboard packs.
14 pcs. – contour cell blisters (8) – cardboard packs.
14 pcs. – contour cell blisters (9) – cardboard packs.
14 pcs. – contour cell blisters (10) – cardboard packs.
10 pcs. – jars – cardboard packs.
20 pcs. – jars – cardboard packs.
30 pcs. – jars – cardboard packs.
40 pcs. – jars – cardboard packs.
50 pcs. – jars – cardboard packs.
60 pcs. – jars – cardboard packs.
70 pcs. – jars – cardboard packs.
80 pcs. – jars – cardboard packs.
90 pcs. – jars – cardboard packs.
100 pcs. – jars – cardboard packs.
Concentrate for solution for infusion 20 mg/ml: 5 ml amp. 10 pcs.
Marketing Authorization Holder
Grotex, LLC (Russia)
Manufactured By
Grotex, LLC (Russia)
Dosage Form
|
Pentoxifylline | Concentrate for solution for infusion 20 mg/ml: 5 ml amp. 10 pcs. |
Dosage Form, Packaging, and Composition
Concentrate for solution for infusion in the form of a clear, colorless or with a yellowish tint liquid.
| 1 ml | |
| Pentoxifylline | 20 mg |
Excipients: sodium chloride – 6 mg, sodium dihydrogen phosphate dihydrate – 1 mg, sodium hydroxide solution 1M – to pH 6.0 – 8.0, water for injection – to 1 ml.
5 ml – polyethylene ampoules (10) – cardboard packs.
Solution for injection 20 mg/ml: amp. 10 pcs.
Marketing Authorization Holder
Dalkhimpharm, JSC (Russia)
Dosage Form
|
Pentoxifylline | Solution for injection 20 mg/ml: amp. 10 pcs. |
Dosage Form, Packaging, and Composition
Solution for injection clear, colorless or slightly yellowish.
| 1 ml | |
| Pentoxifylline | 20 mg |
Excipients: sodium chloride – 6 mg, sodium dihydrogen phosphate dihydrate – 1 mg, sodium hydroxide solution 1M – to pH 6.0 – 8.0, water for injection – to 1 ml.
5 ml – ampoules (10) – cardboard boxes.
5 ml – ampoules (5) – contour cell blisters (2) – cardboard packs.
Enteric-coated tablets, 100 mg: 60 pcs.
Marketing Authorization Holder
Lekhim, JSC (Ukraine)
Dosage Form
|
Pentoxifylline | Enteric-coated tablets, 100 mg: 60 pcs. |
Dosage Form, Packaging, and Composition
| Enteric-coated tablets | 1 tab. |
| Pentoxifylline | 100 mg |
10 pcs. – blisters (6) – cardboard packs.
Concentrate for solution for intravenous and intra-arterial administration 100 mg/5 ml: amp. 5, 10 or 20 pcs.
Marketing Authorization Holder
N.A. Semashko Moscow Chemical Pharmaceutical Preparations, JSC (Russia)
Dosage Form
|
Pentoxifylline | Concentrate for solution for intravenous and intra-arterial administration 100 mg/5 ml: amp. 5, 10 or 20 pcs. |
Dosage Form, Packaging, and Composition
| Concentrate for preparation of solution for intravenous and intra-arterial administration | 1 ml | 1 amp. |
| Pentoxifylline | 20 mg | 100 mg |
5 ml – ampoules (10) – cardboard packs.
5 ml – ampoules (10) – contour cell blisters (1) – cardboard packs.
5 ml – ampoules (10) – contour cell blisters (2) – cardboard packs.
5 ml – ampoules (5) – contour cell blisters (1) – cardboard packs.
5 ml – ampoules (5) – contour cell blisters (2) – cardboard packs.
Enteric-coated tablets, 100 mg: 60 pcs.
Marketing Authorization Holder
N.A. Semashko Moscow Chemical Pharmaceutical Preparations, JSC (Russia)
Dosage Form
|
Pentoxifylline | Enteric-coated tablets, 100 mg: 60 pcs. |
Dosage Form, Packaging, and Composition
| Enteric-coated tablets | 1 tab. |
| Pentoxifylline | 100 mg |
10 pcs. – contour cell packs (6) – cardboard packs.
Extended-release coated tablets, 400 mg: 30 or 60 pcs.
Marketing Authorization Holder
Novosibkhimpharm, JSC (Russia)
Dosage Form
|
Pentoxifylline | Extended-release coated tablets, 400 mg: 30 or 60 pcs. |
Dosage Form, Packaging, and Composition
| Extended-release coated tablets | 1 tab. |
| Pentoxifylline | 400 mg |
10 pcs. – blisters (3) – cardboard packs.
10 pcs. – blisters (6) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
60 pcs. – polymer jars (1) – cardboard packs.
Solution for intravenous injection 100 mg/5 ml: amp. 5, 10, or 20 pcs.
Marketing Authorization Holder
Novosibkhimpharm, JSC (Russia)
Dosage Form
|
Pentoxifylline | Solution for intravenous injection 100 mg/5 ml: amp. 5, 10, or 20 pcs. |
Dosage Form, Packaging, and Composition
| Solution for intravenous administration | 1 ml | 1 amp. |
| Pentoxifylline | 20 mg | 100 mg |
5 ml – ampoules (10) – cardboard packs.
5 ml – ampoules (10) – plastic contour packs (1) – cardboard packs.
5 ml – ampoules (10) – plastic contour packs (2) – cardboard packs.
5 ml – ampoules (5) – plastic contour packs (2) – cardboard packs.
5 ml – ampoules (5) – plastic contour packs (1) – cardboard packs.
Enteric-coated tablets, 100 mg: 30 or 60 pcs.
Marketing Authorization Holder
Novosibkhimpharm, JSC (Russia)
Dosage Form
|
Pentoxifylline | Enteric-coated tablets, 100 mg: 30 or 60 pcs. |
Dosage Form, Packaging, and Composition
| Enteric-coated tablets | 1 tab. |
| Pentoxifylline | 100 mg |
10 pcs. – blisters (3) – cardboard packs.
10 pcs. – blisters (6) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
60 pcs. – polymer jars (1) – cardboard packs.
Solution for intravenous and intra-arterial administration 100 mg/5 ml: amp. 10 pcs.
Marketing Authorization Holder
Microgen NPO, JSC (Russia)
Dosage Form
|
Pentoxifylline | Solution for intravenous and intra-arterial administration 100 mg/5 ml: amp. 10 pcs. |
Dosage Form, Packaging, and Composition
| Solution for intravenous and intra-arterial administration | 1 ml | 1 amp. |
| Pentoxifylline | 20 mg | 100 mg |
5 ml – ampoules (10) – cardboard packs.
5 ml – ampoules (10) – cardboard boxes.
Enteric-coated film-coated tablets, 100 mg: 60 pcs.
Marketing Authorization Holder
Organika, JSC (Russia)
Dosage Form
|
Pentoxifylline | Enteric-coated film-coated tablets, 100 mg: 60 pcs. |
Dosage Form, Packaging, and Composition
| Enteric-coated film-coated tablets | 1 tab. |
| Pentoxifylline | 100 mg |
60 pcs. – polymer bottles (1) – cardboard packs.
60 pcs. – dark glass bottles (1) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
Solution for intravenous and intra-arterial administration 100 mg/5 ml: amp. 10 pcs.
Marketing Authorization Holder
Organika, JSC (Russia)
Dosage Form
|
Pentoxifylline | Solution for intravenous and intra-arterial administration 100 mg/5 ml: amp. 10 pcs. |
Dosage Form, Packaging, and Composition
| Solution for intravenous and intra-arterial administration | 1 ml | 1 amp. |
| Pentoxifylline | 20 mg | 100 mg |
5 ml – ampoules (10) – cardboard packs.
Concentrate for solution for intravenous and intra-arterial administration 100 mg/5 ml: amp. 5 or 10 pcs.
Marketing Authorization Holder
Promomed Rus LLC (Russia)
Dosage Form
|
Pentoxifylline | Concentrate for solution for intravenous and intra-arterial administration 100 mg/5 ml: amp. 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
| Concentrate for solution for intravenous and intra-arterial administration | 1 ml | 1 amp. |
| Pentoxifylline | 20 mg | 100 mg |
5 ml – ampoules (10) – cardboard packs.
5 ml – ampoules (5) – contour cell packs (2) – cardboard packs.
5 ml – ampoules (5) – contour cell packs (1) – cardboard packs.
Concentrate for solution for intravenous and intra-arterial administration 20 mg/1 ml: 5 or 10 ml amp. 5 or 10 pcs.
Marketing Authorization Holder
Slavic Pharmacy, LLC (Russia)
Dosage Form
|
Pentoxifylline | Concentrate for solution for intravenous and intra-arterial administration 20 mg/1 ml: 5 or 10 ml amp. 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Concentrate for solution for intravenous and intra-arterial administration as a clear, colorless or light yellow liquid.
| 1 ml | |
| Pentoxifylline | 20 mg |
Excipients: sodium chloride – 6 mg, sodium dihydrogen phosphate dihydrate – 1 mg, sodium hydroxide solution 0.1 M – to pH 6.0-8.0, water for injection – up to 1 ml.
5 ml – polymer ampoules (5) – cardboard packs.
5 ml – polymer ampoules (10) – cardboard packs.
10 ml – polymer ampoules (5) – cardboard packs.
10 ml – polymer ampoules (10) – cardboard packs.
Enteric-coated tablets, 100 mg: 10, 20, 30, 40, 50, or 60 pcs.
Marketing Authorization Holder
Uralbiopharm, JSC (Russia)
Dosage Form
|
Pentoxifylline | Enteric-coated tablets, 100 mg: 10, 20, 30, 40, 50, or 60 pcs. |
Dosage Form, Packaging, and Composition
| Enteric-coated tablets | 1 tab. |
| Pentoxifylline | 100 mg |
10 pcs. – blisters (6) – cardboard packs.
60 pcs. – dark glass jars (1) – cardboard packs.
10 pcs. – blisters (1) – cardboard packs.
10 pcs. – blisters (2) – cardboard packs.
10 pcs. – blisters (3) – cardboard packs.
10 pcs. – blisters (4) – cardboard packs.
10 pcs. – blisters (5) – cardboard packs.
20 pcs. – dark glass jars (1) – cardboard packs.
30 pcs. – dark glass jars (1) – cardboard packs.
40 pcs. – dark glass jars (1) – cardboard packs.
50 pcs. – dark glass jars (1) – cardboard packs.
Enteric-coated film-coated tablets, 100 mg: 60 pcs.
Marketing Authorization Holder
Pharmproekt, JSC (Russia)
Dosage Form
|
Pentoxifylline | Enteric-coated film-coated tablets, 100 mg: 60 pcs. |
Dosage Form, Packaging, and Composition
| Enteric-coated film-coated tablets | 1 tab. |
| Pentoxifylline | 100 mg |
60 pcs. – polymer bottles (1) – cardboard packs.
10 pcs. – blisters (6) – cardboard packs.
Extended-release tablets 600 mg: 30 or 50 pcs.
Marketing Authorization Holder
Sandoz, d.d. (Slovenia)
Manufactured By
Salutas Pharma, GmbH (Germany)
Dosage Form
|
Pentoxifylline Sandoz | Extended-release tablets 600 mg: 30 or 50 pcs. |
Dosage Form, Packaging, and Composition
Extended-release tablets white, oblong, biconvex, with a score on both sides.
| 1 tab. | |
| Pentoxifylline | 600 mg |
Excipients: copovidone – 60 mg, hypromellose K 15 M – 32 mg, hypromellose K 100 M – 46 mg, talc – 14 mg, magnesium stearate – 8 mg.
10 pcs. – blisters (3) – cardboard packs.
10 pcs. – blisters (5) – cardboard packs.
Enteric-coated film-coated tablets 100 mg
Marketing Authorization Holder
Velpharm, LLC (Russia)
Dosage Form
|
Pentoxifylline Velpharm | Enteric-coated film-coated tablets 100 mg |
Dosage Form, Packaging, and Composition
Enteric-coated film-coated tablets
| 1 tab. | |
| Pentoxifylline | 100 mg |
10 pcs. – jars – cardboard packs (10 pcs.) – By prescription
10 pcs. – contour cell packs – cardboard packs (10 pcs.) – By prescription
10 pcs. – contour cell packs (10 pcs.) – cardboard packs (100 pcs.) – By prescription
10 pcs. – contour cell packs (2 pcs.) – cardboard packs (20 pcs.) – By prescription
10 pcs. – contour cell packs (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – contour cell packs (4 pcs.) – cardboard packs (40 pcs.) – By prescription
10 pcs. – contour cell packs (5 pcs.) – cardboard packs (50 pcs.) – By prescription
10 pcs. – contour cell packs (6 pcs.) – cardboard packs (60 pcs.) – By prescription
10 pcs. – contour cell packs (7 pcs.) – cardboard packs (70 pcs.) – By prescription
10 pcs. – contour cell packs (8 pcs.) – cardboard packs (80 pcs.) – By prescription
10 pcs. – contour cell packs (9 pcs.) – cardboard packs (90 pcs.) – By prescription
100 pcs. – jars – cardboard packs (100 pcs.) – By prescription
14 pcs. – contour cell packs – cardboard packs (14 pcs.) – By prescription
14 pcs. – contour cell packs (10 pcs.) – cardboard packs (140 pcs.) – By prescription
14 pcs. – contour cell packs (2 pcs.) – cardboard packs (28 pcs.) – By prescription
14 pcs. – contour cell packs (3 pcs.) – cardboard packs (42 pcs.) – By prescription
14 pcs. – contour cell packs (4 pcs.) – cardboard packs (56 pcs.) – By prescription
14 pcs. – contour cell packs (5 pcs.) – cardboard packs (70 pcs.) – By prescription
14 pcs. – contour cell packs (6 pcs.) – cardboard packs (84 pcs.) – By prescription
14 pcs. – contour cell packs (7 pcs.) – cardboard packs (98 pcs.) – By prescription
14 pcs. – contour cell packs (8 pcs.) – cardboard packs (112 pcs.) – By prescription
14 pcs. – contour cell packs (9 pcs.) – cardboard packs (126 pcs.) – By prescription
20 pcs. – jars – cardboard packs (20 pcs.) – By prescription
30 pcs. – jars – cardboard packs (30 pcs.) – By prescription
40 pcs. – jars – cardboard packs (40 pcs.) – By prescription
50 pcs. – jars – cardboard packs (50 pcs.) – By prescription
60 pcs. – jars – cardboard packs (60 pcs.) – By prescription
70 pcs. – jars – cardboard packs (70 pcs.) – By prescription
80 pcs. – jars – cardboard packs (80 pcs.) – By prescription
90 pcs. – jars – cardboard packs (90 pcs.) – By prescription
Film-coated tablets, 100 mg: 60 pcs.
Marketing Authorization Holder
Akrikhin Chemical and Pharmaceutical Plant, JSC (Russia)
Dosage Form
|
Pentoxifylline-Akri® | Film-coated tablets, 100 mg: 60 pcs. |
Dosage Form, Packaging, and Composition
| Film-coated tablets | 1 tab. |
| Pentoxifylline | 100 mg |
10 pcs. – contour cell packs (6) – cardboard packs.
Tablets 200 mg: 10, 20, 30, 40, or 50 pcs.
Marketing Authorization Holder
Darnitsa Pharmaceutical Firm, PJSC (Ukraine)
Dosage Form
|
Pentoxifylline-Darnitsa | Tablets 200 mg: 10, 20, 30, 40, or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Pentoxifylline | 200 mg |
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
Concentrate for solution for intravenous and intra-arterial administration 100 mg/5 ml: amp. 10 pcs.
Marketing Authorization Holder
Darnitsa Pharmaceutical Firm, PJSC (Ukraine)
Dosage Form
|
Pentoxifylline-Darnitsa | Concentrate for solution for intravenous and intra-arterial administration 100 mg/5 ml: amp. 10 pcs. |
Dosage Form, Packaging, and Composition
| Concentrate for solution for intravenous and intra-arterial administration | 1 ml | 1 amp. |
| Pentoxifylline | 20 mg | 100 mg |
5 ml – ampoules (10) – cardboard packs.
Concentrate for solution for injection 100 mg/5 ml: amp. 5, 10, or 20 pcs.
Marketing Authorization Holder
Mir Chemical and Pharmaceutical Concern, LLC (Russia)
Dosage Form
|
Pentoxifylline-Eskom | Concentrate for solution for injection 100 mg/5 ml: amp. 5, 10, or 20 pcs. |
Dosage Form, Packaging, and Composition
| Concentrate for solution for injection | 1 ml | 1 amp. |
| Pentoxifylline | 20 mg | 100 mg |
5 ml – ampoules (10) – cardboard packs.
5 ml – ampoules (10) – contour plastic packs (1) – cardboard packs.
5 ml – ampoules (10) – contour plastic packs (2) – cardboard packs.
5 ml – ampoules (5) – contour plastic packs (2) – cardboard packs.
5 ml – ampoules (5) – contour plastic packs (1) – cardboard packs.
Enteric-coated tablets 100 mg: 10, 20, 30, 40, 60, or 120 pcs.
Marketing Authorization Holder
FP Obolenskoe, JSC (Russia)
Dosage Form
|
Pentoxifylline-FPO® | Enteric-coated tablets 100 mg: 10, 20, 30, 40, 60, or 120 pcs. |
Dosage Form, Packaging, and Composition
| Enteric-coated tablets | 1 tab. |
| Pentoxifylline | 100 mg |
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
Capsules 200 mg: 10, 40, or 50 pcs.
Marketing Authorization Holder
Minskintercaps Up (Republic Of Belarus)
Dosage Form
|
Pentoxifylline-MIC | Capsules 200 mg: 10, 40, or 50 pcs. |
Dosage Form, Packaging, and Composition
| Capsules | 1 caps. |
| Pentoxifylline | 200 mg |
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
Retard tablets, film-coated, 400 mg: 20 or 90 pcs.
Marketing Authorization Holder
Teva Pharmaceutical Industries, Ltd. (Israel)
Dosage Form
|
Pentoxifylline-Teva | Retard tablets, film-coated, 400 mg: 20 or 90 pcs. |
Dosage Form, Packaging, and Composition
| Retard tablets, film-coated | 1 tab. |
| Pentoxifylline | 400 mg |
10 pcs. – contour cell packs (2) – cardboard packs.
6 pcs. – contour cell packs (15) – cardboard packs.
![Pentoxifylline [Tablets, Capsules, Solution, Concentrate] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Pentoxifylline [Tablets, Capsules, Solution, Concentrate] 2")